Srinibas Sahu
BACKGROUND Diabetes mellitus is a metabolic disorder due to absolute or relative deficiency of insulin or insulin resistance which is characterized by hyperglycaemia. To evaluate the efficacy of Rosuvastatin and Atorvastatin in correcting dyslipidaemia in type 2 diabetic patients. MATERIAL AND METHODS A retrospective data analysis was performed where uncomplicated type 2 diabetes mellitus patients with dyslipidaemia but with good glycaemic control, who received either Rosuvastatin 10 mgs or Atorvastatin in 20 mgs. The various lipid parameters were recorded at the start of statin treatment and after 12 weeks of treatment. Results were compared, and statistical analysis was done. RESULTS Both drugs reduced the levels of Total cholesterol, Serum triglyceride & LDL-cholesterol levels and raised the serum level of HDL-cholesterol. The mean changes for Rosuvastatin & Atorvastatin were 74.89 ± 10.04, 50.20 ± 14.09, 74.45 ± 10.12 & 43.75 ± 5.69, 31.88 ± 2.17, 46.36 ± 6.22 respectively for the bad cholesterols and the mean rise in the serum level of good cholesterol was 9.6 ± 0.10 & 8.94 ± 0.98. The observations were statistically significant. CONCLUSION Rosuvastatin was found to be a better drug for managing dyslipidaemia in type 2 diabetics.
